Related Experiment Video
Updated: Jul 5, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
Penetration and accumulation of moxifloxacin in uterine tissue
Heino Stass1, Dagmar Kubitza, Baybur Aydeniz
1Bayer HealthCare AG, Wuppertal, Germany. heino.stass@bayerhealthcare.com
Objective:
To determine whether moxifloxacin penetrates the uterine tissue and accumulates at levels sufficient to eradicate the major pathogens causing pelvic inflammatory disease (PID).
Method:
In a prospective, multicenter, open-label, parallel-group study we determined the concentration of moxifloxacin in plasma and uterine tissue after a single, 400-mg intravenous dose of moxifloxacin. Study participants were randomized for time of tissue sampling, which was performed 1, 2, 4, 7, or 24 hours following the moxifloxacin infusion.
Results:
Of 43 participants, 40 were randomized to tissue sampling. Moxifloxacin accumulated in uterine tissue and concentrations were highest 1 hour after infusion in both plasma and tissue. Tissue to plasma ratios remained between 1.7 and 2.1 for 24 hours. Moxifloxacin was found to be safe and well tolerated.
Conclusion:
Based on known minimum inhibitory concentration data, the uterine tissue concentrations of moxifloxacin achieved over 24 hours would be sufficient to eradicate the range of bacterial pathogens responsible for PID.
Insights
Moxifloxacin effectively penetrates uterine tissue, reaching concentrations adequate for eradicating common pelvic inflammatory disease (PID) pathogens. This antibiotic demonstrates safety and tolerability for PID treatment.
Area of Science:
- Pharmacology
- Infectious Diseases
- Gynecology
Background:
- Pelvic inflammatory disease (PID) is a serious infection.
- Effective antibiotic penetration into uterine tissue is crucial for PID treatment.
- Moxifloxacin is a broad-spectrum antibiotic.
Purpose of the Study:
- To assess moxifloxacin's uterine tissue penetration.
- To determine if moxifloxacin concentrations are sufficient to treat PID pathogens.
Main Methods:
- Prospective, multicenter, open-label study.
- Single 400-mg intravenous dose of moxifloxacin administered.
- Uterine tissue and plasma concentrations measured at 1, 2, 4, 7, and 24 hours post-infusion.
Main Results:
- Moxifloxacin achieved significant uterine tissue accumulation.
- Peak concentrations in plasma and tissue occurred at 1 hour.
- Tissue-to-plasma ratios ranged from 1.7 to 2.1 over 24 hours.
- Moxifloxacin was safe and well-tolerated.
Conclusions:
- Achieved uterine tissue concentrations of moxifloxacin exceed minimum inhibitory concentrations for common PID pathogens.
- Moxifloxacin is a promising therapeutic option for PID.
Related Concept Videos
Intrauterine Drug Delivery Systems
Uterine Tubes
Inhibitors of Bacterial DNA Synthesis
Uterus and Cervix
The uterus is securely anchored within the pelvic cavity by paired broad ligaments on either side. It is further stabilized by three pairs of...
Physiological Barriers
The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...

